About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Chapters
Books
News
Editorials
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Scientometrics
Impact Factor
Discipline Ranks
H-Index
G-Index
Articles
Citations
Article Citations
Citation Distribution
Search This Journal
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
exaly
›
Journals
›
Retina
›
Top Articles
Retina
Ophthalmology
3.6
(top 4%)
Impact Factor
3.9
(top 4%)
extended IF
135
(top 2%)
H-Index
1.6K
authors
8.5K
papers
191.1K
citations
3.9K
citing journals
22K
citing authors
Most Cited Articles of Retina
Title
Year
Citations
Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy
2009
725
IMAGE ARTIFACTS IN OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY
2015
684
Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration
2006
648
IDIOPATHIC POLYPOIDAL CHOROIDAL VASCULOPATHY (IPCV)
1990
620
Retinal angiomatous proliferation in age-related macular degeneration
2001
595
Anatomical correlates to the bands seen in the outer retina by optical coherence tomography: literature review and model
2011
543
Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration
2006
518
Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy
1995
510
Transconjunctival sutureless 23-gauge vitrectomy
2005
474
Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage
2006
443
EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy
2012
442
Risks of intravitreous injection: a comprehensive review
2004
434
Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration
2006
432
Fundus autofluorescence imaging: review and perspectives
2008
416
Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study
2006
415
Pathologic findings in pathologic myopia
1992
404
INTRAVITREAL TRIAMCINOLONE ACETONIDE IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION
2000
389
Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema
2006
380
DIGITAL INDOCYANINE GREEN VIDEOANGIOGRAPHY AND CHOROIDAL NEOVASCULARIZATION
1992
358
Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration
2002
351
Indocyanine green videoangiography of older patients with central serous chorioretinopathy
1996
346
Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study
2003
333
RETINAL VASCULAR PERFUSION DENSITY MAPPING USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN NORMALS AND DIABETIC RETINOPATHY PATIENTS
2015
319
Pachychoroid pigment epitheliopathy
2013
314
Triamcinolone acetonide as an aid to visualization of the vitreous and the posterior hyaloid during pars plana vitrectomy
2000
313
0
1
2
next
How are inpact factors calculated?
The impact factor (IF) is calculated by counting citations from peer-reviewed journals only.
extended IF
also counts citations from books and conference papers. However, no patent, abstract, working papers, online documents, etc., are covered.
site/software ©
exaly
; All materials licenced under
CC by-SA
.